The world's first anti-thorium drug, Austedo (Antitan ®), is listed in China to treat Huntington's disease and delayed motor disorders!

May 23, 2020 /prnewswireBIOON/ -- China's National Drug Administration (NMPA) has approved Austedo (Chinese commodity name: Antitan ®, generic name: deutetrabenazine, thorium beninatablets) for the treatment of Huntington's disease (HD)-related dance diseases and delayed movement disorders (TDD) in adult patientsThe application for the drug's listing was previously included in the priority review by the NMPA Drug Review Centre (CDE)It's worth noting that Austedo (Antitan ®) is the first approved drug in the world, and China is the second country in the world to approve Austedo after the United Statesas part of the rapid review process, NMPA added Austedo to the List of Clinically Needed Foreign New Drugs (First Batch) and gave priority reviews, resulting in the completion of the approval process within four months for the benefit of Chinese patientsThis is the second approval and expected launch of treanda ,®, generic name: bendamustine, benzoisin, in ChinaTeva will independently commercialize the drug in China"Austedo's approval in China is an exciting milestone for Teva," said Gianfranco Nazzi, executive vice president of international marketsWe are fulfilling our mission to improve the lives of our patients by providing a new treatmentWe look forward to providing more essential medicines to Our Product Portfolio for Our Chinese Patients and promoting organic growth to expand our presence in this important market"
Huntington's disease (HD) is a rare and fatal neurodegenerative disease with a total prevalence rate of 0.40 per 100,000 in Asia and an average age of 40 years of onsetDance disease is one of the most significant physical manifestations of the disease, occurring in about 90% of patientsdelayed motor disorder (TD) is a movement disorder characterized by repetitive and uncontrollable movement of the tongue, lips, face, torso and limbsA disease that is often debilitating and affects about 500,000 people in the United States, usually caused by drugs commonly used to treat mental illnesses such as schizophrenia and bipolar disorder, or the gastrointestinal drug metoclopramidein China, the prevalence of TD in patients with schizophrenia who have been taking antipsychotic drugs for a long time is 33.7 percent, possibly caused by certain medications for mental health conditions, meaning that up to one-third of people with schizophrenia may have TDThe disease not only affects the patient's treatment compliance, but also affects the patient's quality of life and social function Austedo is the first drug in China to approve the treatment of TD Austedo: the world's first radon drug
The active pharmaceutical ingredient of Austedo (Antitan®) is deutetrabenazine (thorium-deprehn), a small-molecule oral inhibitor targeted at cystic monoamine transporter 2 (VMAT2), which regulates levels of dopamine, 5-serotonin, epinephrine, and norepinephrine in the brain deutetrabenazine is a thorium drug that has been marketed for huntingtondisease treatment drug butylnazine After the geniquin, pharmacokinetic scars are improved and the half-life is significantly longer, allowing for lower therapeutic doses Austedo is the world's first approved radon drug In the United States, Austedo received FDA approval in April 2017 to treat Huntington's disease-related dance disease In August 2017, the FDA approve a new indication of Austedo for the treatment of delayed motor disorders in adults titivis: the pioneer of the field of radon
the xenon technology the thorium (D) element spout is very rich in nature, can form a stable molecular bond with other elements In an adult, the average d content is about 2g Although D and hydrogen (H) are essentially the same in atomic size and shape, there is also a fundamental difference between D and H, i.e D contains an extra neutron As a result, the chemical bonds formed by D and carbon (C) are more stable than the chemical bonds formed by H and C In general, the stability of the D-C chemical bond is 6-9 times higher than that of the H-C chemical bond, which has a very important effect in drug development, as drug metabolism often involves the rupture of the H-C chemical bond traditional method of drug discovery, it takes a long time and has a high failure rate The chemical method of radon, usually based on the listed drugs, is more efficient and less costly to develop The use of thorium (radon substitution) can enhance some of the performance of the drug: because D and C can form a more stable chemical bond, D can in some cases change the metabolism of the drug, including improved metabolic stability, reduce the formation of toxic metabolites, increase the formation of the required active metabolites, or a combination of these effects Compared to the corresponding non-pyridoous analogues, the half-life of the niobium compound sin is longer in the body and the system exposure increases, which may have therapeutic benefits, such as increased safety, effectiveness, tolerance and convenience normal, niobium compounds are expected to retain biochemical efficacy and selectivity similar to their hydrogenated analogues The effect of radon substitution on metabolic properties is highly dependent on the specific molecular position of D-replace H However, the metabolic effects of radon substitution, if any, are unpredictable, even in compounds with similar chemical structures at present, a number of pharmaceutical companies are developing drugs currently on the market for thorium drugs For example, Concert has developed a new product, CTP-543, using the jak1/JAK2 inhibitor ruxolitinib, using thorium chemistry technology, which has achieved strong results in the treatment of spot baldness Ruxolitinib has been approved in the United States under the brand name Jakafi for the treatment of a variety of blood diseases Ruxolitinib's niobium chemistry modification can alter the pharmacokinetics of the human body, thereby enhancing its use as a spot treatment (biovalleybioon.com) original origin: China app
roves AUSTEDO? For The For The Tria Associates with Huntington's Disease and Tardive Dyskinesia in Adults